Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

An Institutional Retrospective Study on Recognizing the Delay in Multiple Myeloma Diagnosis

Nima Ghalehsari, MD, Pragnan Kancharla, MD MBBS, Neil S Nimkar, MD, Anita Mazloom, MD, Farah Ashraf, DO, Angelica Singh, MD, Mendel Goldfinger, MD

Blood (2019) 134 (Supplement_1): 3430.

https://doi.org/10.1182/blood-2019-127625

Published: 2019

Journal Articles

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Daniel Hofbauer, Dimitrios Mougiakakos, MD, Maike Büttner-Herold, Frank Neumann, PhD, Jens Nolting, Savita Bisht, Robert Zeiser, MD, Shaima'A Hamarsheh, MSc,BSc, Stefano Ricagno, PhD, Mario Zaiss, Martin Eberhardt, Martin Boettcher, PhD, Katrin Bitterer, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 2314.

https://doi.org/10.1182/blood-2019-123958

Published: 2019

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Daniele Tibullo, PhD, Anna Longo, PhD, Alessandra Romano, MD PhD, Alessandro Barbato, Cesarina Giallongo, PhD, Michelino Di Rosa, PhD, Carmelina Daniela Anfuso, Gabriella Lupo, Concetta Conticello, MD, Nunzio Vicario, PhD, Rosario Gulino, PhD, Rosalba Parenti, PhD, Giuseppe A. Palumbo, MD PhD, Giovanni Li Volti, MD PhD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4345.

https://doi.org/10.1182/blood-2019-129927

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients

Sandra Sauer, MD, Christos Sachpekidis, Simone Brandelik, Daniel Spira, Stefanie Huhn, Barbara Wagner, Manuela Hummel, Antonia Dimitrakopoulou-Strauss, Jennifer Mosebach, Stefan Delorme, Hartmut Goldschmidt, MD, Carsten Müller-Tidow, MD, Jens Hillengass, MD

Blood (2018) 132 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2018-99-115201

Published: 2018

Journal Articles

Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base

Xavier Orcutt, BA, Peter Barth, MD, Adam J Olszewski, MD

Blood (2018) 132 (Supplement 1): 3230.

https://doi.org/10.1182/blood-2018-99-110108

Published: 2018

Journal Articles

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Monika Szarejko, Artur Jurczyszyn, MD, Jan Dürig, Sara Bringhen, Barbara Gamberi, MD, Angelo Vacca, Jorge Castellano Acosta, MD, Guy Lemaillet, PhD, Cedric Cortijo, PhD, Bansod Sudhir, Norbert Grząśko, MDPhD

Blood (2018) 132 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2018-99-112859

Published: 2018

Journal Articles

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Joanne Sowter, MSc, Dimitrios A Koutoukidis, PhD, Maggie Heinrich, PhD, Orla McCourt, MSc, Allan Hackshaw, Rebecca Beeken, PhD, Dunnya De-Silva, Stephanie Philpott, MSc, Ali Rismani, MBBS, Neil K Rabin, MD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, Charalampia Kyriakou, MD PhD, Atul Mehta, FRCP, Bruce Paton, PhD, Abigail Fisher, PhD, Kwee Yong, PhD

Blood (2018) 132 (Supplement 1): 974.

https://doi.org/10.1182/blood-2018-99-111403

Published: 2018

Journal Articles

Altering Glycosphingolipid Composition to Improve Multiple Myeloma Bone Complication

Houfu Leng, MSc, DPhil, MBBS, BSc, Adel Ersek, PhD, Emma Morris, DPhil, Beatriz Gamez Molina, PhD, Claire M. Edwards, PhD, Nicole Horwood, PhD

Blood (2018) 132 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2018-99-112237

Published: 2018

Journal Articles

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Jingsong He, MD, Qingxiao Chen, MS, Yang Yang, MD, Yi Li, MD, Li Yang, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 5392.

https://doi.org/10.1182/blood.V130.Suppl_1.5392.5392

Published: 2017

Journal Articles

AURKA Regulates the Mechanism of ATR Mediated DNA Damage Response about Drug Resistance in Multiple Myeloma

Zhang Shuaishuai, MD, Yu Qin, An Gang, MD, Mu Hao, PhD, Yan Xu, MD, Shuhui Deng, Tengteng Yu, Wen Zhou, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 5354.

https://doi.org/10.1182/blood.V130.Suppl_1.5354.5354

Published: 2017

Journal Articles

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

Reinaldo Franqui-Machin, Mu Hao, PhD, Bai Hua, Zhimin Gu, PhD, Xin Zhan, Hongwei Xu, Hasem Habelhah, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Lugui Qiu, MD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2017) 130 (Supplement 1): 593.

https://doi.org/10.1182/blood.V130.Suppl_1.593.593

Published: 2017

Journal Articles

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Gabriel M. Pagnotti, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1775.

https://doi.org/10.1182/blood.V130.Suppl_1.1775.1775

Published: 2017

Journal Articles

Bone-Targeted Pharmacological Inhibition of Notch Signaling As a Novel Approach to Inhibit Myeloma Growth and Bone Destruction

Jesus Delgado-Calle, PhD, Gerald Wu, Jessica Nelson, Emily G Atkinson, Kevin McAndrews, Lifeng Xiao, Frank H Ebetino, Robert K Boeckman, Jr., David David Roodman, MD PhD, Teresita Bellido

Blood (2017) 130 (Supplement 1): 4419.

https://doi.org/10.1182/blood.V130.Suppl_1.4419.4419

Published: 2017

Journal Articles

T Cells Trafficking to Bone Marrow Have Different Characteristics from Those to Other Organs in an Immune-Mediated Bone Marrow Failure Mouse Model

Zenghua Lin, MD, Xingmin Feng, PhD, Wanling Sun, MD PhD, Zhijie Wu, MD PhD, Maile K Hollinger, BA, Jichun Chen, PhD, Hong Liu, MD PhD, Neal S. Young, MD

Blood (2017) 130 (Supplement 1): 2455.

https://doi.org/10.1182/blood.V130.Suppl_1.2455.2455

Published: 2017

Journal Articles

Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs

Jesus Delgado-Calle, PhD, Emily G Atkinson, Jessica Nelson, Noriyoshi Kurihara, DDS, PhD, Carlos Galmarini, David David Roodman, MD PhD, Teresita Bellido

Blood (2017) 130 (Supplement 1): 3065.

https://doi.org/10.1182/blood.V130.Suppl_1.3065.3065

Published: 2017

Journal Articles

C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcγRII-p38MAPK-Twist Axis

Jing Yang, PhD, Zhiqiang Liu, PhD, Huan Liu, PhD, Jin He, Jianling Yang, PhD, Pei Lin, MDDM,MDC, Qiang WANG, PhD, Juan Du, PhD MD, Wencai Ma, Richard E Davis, BSPharm, MS, Robert Z. Orlowski, MD PhD, Jian Hou, MD, Qing Yi, MD PhD

Blood (2017) 130 (Supplement 1): 3043.

https://doi.org/10.1182/blood.V130.Suppl_1.3043.3043

Published: 2017

Journal Articles

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Qingxiao Chen, MS, Jingsong He, MD, Huiyao Gu, Xi Huang, MD, Jing Chen, MD, Zhang En Fan, Xing Guo, MD, Haimeng Yan, He Huang, MD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 3079.

https://doi.org/10.1182/blood.V130.Suppl_1.3079.3079

Published: 2017

NARROW

An Institutional Retrospective Study on Recognizing the Delay in Multiple Myeloma Diagnosis

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients

Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Altering Glycosphingolipid Composition to Improve Multiple Myeloma Bone Complication

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

AURKA Regulates the Mechanism of ATR Mediated DNA Damage Response about Drug Resistance in Multiple Myeloma

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Bone-Targeted Pharmacological Inhibition of Notch Signaling As a Novel Approach to Inhibit Myeloma Growth and Bone Destruction

T Cells Trafficking to Bone Marrow Have Different Characteristics from Those to Other Organs in an Immune-Mediated Bone Marrow Failure Mouse Model

Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs

C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcγRII-p38MAPK-Twist Axis

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only